Mustang Bio Management
Management criteria checks 4/4
Mustang Bio's CEO is Manny Litchman, appointed in Apr 2017, has a tenure of 7.75 years. total yearly compensation is $501.84K, comprised of 95.8% salary and 4.2% bonuses, including company stock and options. directly owns 0.16% of the company’s shares, worth $19.56K. The average tenure of the management team and the board of directors is 2.9 years and 7.8 years respectively.
Key information
Manny Litchman
Chief executive officer
US$501.8k
Total compensation
CEO salary percentage | 95.8% |
CEO tenure | 7.8yrs |
CEO ownership | 0.2% |
Management average tenure | 2.9yrs |
Board average tenure | 7.8yrs |
Recent management updates
Recent updates
Mustang Bio: This Horse May Gallop Still
Sep 23Is Mustang Bio, Inc. (NASDAQ:MBIO) Trading At A 46% Discount?
Aug 09Mustang Bio: The Market Is Missing This Opportunity
May 03Will Mustang Bio (NASDAQ:MBIO) Spend Its Cash Wisely?
Dec 29Mustang Bio: Remains Underfollowed Despite Moving Closer To Pivotal Studies
Sep 14Mustang Bio (MBIO) EHA Investor Presentations - Slideshow
Jun 18Mustang Bio jumps 7% on encouraging MB-106 safety and efficacy data in blood cancers
Jun 11Checking Back In On Mustang Bio
May 26FDA accepts Mustang Bio's MB-106 application in cancer
May 10Here's Why We're Watching Mustang Bio's (NASDAQ:MBIO) Cash Burn Situation
Mar 22What Type Of Shareholders Own The Most Number of Mustang Bio, Inc. (NASDAQ:MBIO) Shares?
Feb 23CEO Compensation Analysis
Date | Total Compensation | Salary | Company Earnings |
---|---|---|---|
Sep 30 2024 | n/a | n/a | -US$23m |
Jun 30 2024 | n/a | n/a | -US$32m |
Mar 31 2024 | n/a | n/a | -US$40m |
Dec 31 2023 | US$502k | US$481k | -US$52m |
Sep 30 2023 | n/a | n/a | -US$63m |
Jun 30 2023 | n/a | n/a | -US$72m |
Mar 31 2023 | n/a | n/a | -US$74m |
Dec 31 2022 | US$636k | US$448k | -US$78m |
Sep 30 2022 | n/a | n/a | -US$78m |
Jun 30 2022 | n/a | n/a | -US$76m |
Mar 31 2022 | n/a | n/a | -US$71m |
Dec 31 2021 | US$885k | US$450k | -US$66m |
Sep 30 2021 | n/a | n/a | -US$67m |
Jun 30 2021 | n/a | n/a | -US$63m |
Mar 31 2021 | n/a | n/a | -US$63m |
Dec 31 2020 | US$1m | US$430k | -US$60m |
Sep 30 2020 | n/a | n/a | -US$56m |
Jun 30 2020 | n/a | n/a | -US$53m |
Mar 31 2020 | n/a | n/a | -US$49m |
Dec 31 2019 | US$517k | US$415k | -US$46m |
Sep 30 2019 | n/a | n/a | -US$42m |
Jun 30 2019 | n/a | n/a | -US$39m |
Mar 31 2019 | n/a | n/a | -US$34m |
Dec 31 2018 | US$606k | US$403k | -US$31m |
Compensation vs Market: Manny's total compensation ($USD501.84K) is about average for companies of similar size in the US market ($USD649.07K).
Compensation vs Earnings: Manny's compensation has been consistent with company performance over the past year.
CEO
Manny Litchman (70 yo)
7.8yrs
Tenure
US$501,838
Compensation
Dr. Manuel Litchman, also known as Manny, M.D. has been the President, Chief Executive Officer and Director at Mustang Bio, Inc. since April 24, 2017 also serves as an Interim CFO since November 15, 2024 a...
Leadership Team
Name | Position | Tenure | Compensation | Ownership |
---|---|---|---|---|
Executive Chairman | 9.7yrs | US$110.00k | 0.034% $ 4.2k | |
President | 7.8yrs | US$501.84k | 0.16% $ 19.6k | |
Controller & Interim Chief Accounting Officer | 1.1yrs | no data | 0.0053% $ 644.1 | |
VP & General Counsel | 3.3yrs | no data | no data | |
Senior VP & Head of Human Resources | 6yrs | no data | no data | |
VP & Head of Regulatory Affairs | 4.8yrs | no data | no data | |
Senior VP & Head of Clinical Development | 3.6yrs | no data | no data | |
Chief Quality Officer | 2yrs | no data | no data | |
Head of CMC Development | 2.4yrs | no data | no data | |
VP and Head of Program & Alliance Leadership | 2yrs | no data | no data | |
VP & Head of Clinical Operations | 2yrs | no data | no data | |
Senior VP & Head of Preclinical Sciences | 2yrs | no data | no data |
2.9yrs
Average Tenure
58yo
Average Age
Experienced Management: MBIO's management team is considered experienced (2.9 years average tenure).
Board Members
Name | Position | Tenure | Compensation | Ownership |
---|---|---|---|---|
Executive Chairman | 9.7yrs | US$110.00k | 0.034% $ 4.2k | |
President | 7.8yrs | US$501.84k | 0.16% $ 19.6k | |
Non-Executive Director | 9.8yrs | US$100.00k | 0.057% $ 7.0k | |
Independent Director | 7.6yrs | US$100.00k | 0.040% $ 4.9k | |
Independent & Non-Executive Director | 9.4yrs | US$100.00k | 0.041% $ 5.1k | |
Independent Director | 7.6yrs | US$110.00k | 0.040% $ 4.9k | |
Director | less than a year | no data | 0.0042% $ 511.8 |
7.8yrs
Average Tenure
64yo
Average Age
Experienced Board: MBIO's board of directors are considered experienced (7.8 years average tenure).
Company Analysis and Financial Data Status
Data | Last Updated (UTC time) |
---|---|
Company Analysis | 2025/01/12 09:39 |
End of Day Share Price | 2025/01/10 00:00 |
Earnings | 2024/09/30 |
Annual Earnings | 2023/12/31 |
Data Sources
The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.
Package | Data | Timeframe | Example US Source * |
---|---|---|---|
Company Financials | 10 years |
| |
Analyst Consensus Estimates | +3 years |
|
|
Market Prices | 30 years |
| |
Ownership | 10 years |
| |
Management | 10 years |
| |
Key Developments | 10 years |
|
* example for US securities, for non-US equivalent regulatory forms and sources are used.
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.
Analysis Model and Snowflake
Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.
Learn about the world class team who designed and built the Simply Wall St analysis model.
Industry and Sector Metrics
Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on .
Analyst Sources
Mustang Bio, Inc. is covered by 6 analysts. 1 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.
Analyst | Institution |
---|---|
Mayank Mamtani | B. Riley Securities, Inc. |
Justin Zelin | B. Riley Securities, Inc. |
Jonathan Aschoff | B. Riley Wealth |